Patents by Inventor Radoslaw Laufer

Radoslaw Laufer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
    Patent number: 8367826
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: February 5, 2013
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Radoslaw Laufer, An-Hu Li, Mark J. Mulvihill, Arno G. Steinig
  • KINASE INHIBITORS AND METHOD OF TREATING CANCER
    Publication number: 20120264800
    Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
    Type: Application
    Filed: June 21, 2012
    Publication date: October 18, 2012
    Applicant: UNIVERSITY HEALTH NETWORKS
    Inventors: Peter Brent SAMPSON, Yong LIU, Sze-Wan LI, Bryan T. FORREST, Heinz W. PAULS, Louise G. EDWARDS, Miklos FEHER, Narendra Kumar B. PATEL, Radoslaw LAUFER, Guohua PAN
  • Kinase inhibitors and method of treating cancer
    Patent number: 8263596
    Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: September 11, 2012
    Assignee: University Health Network
    Inventors: Peter B. Sampson, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Heinz W. Pauls, Louise G. Edwards, Miklos Feher, Narendra Kumar B. Patel, Radoslaw Laufer
  • 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors
    Publication number: 20120196847
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Application
    Filed: April 13, 2012
    Publication date: August 2, 2012
    Inventors: Lee D. Arnold, Heather Coate, Andrew Philip Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark Joseph Mulvihill, Anthony Nigro, Bijoy Panicker, Arno G. Steinig, Qingua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun
  • 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors
    Publication number: 20120077979
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Application
    Filed: December 1, 2011
    Publication date: March 29, 2012
    Inventors: Lee D. Arnold, Heather Coate, Andrew Philip Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark Joseph Mulvihill, Anthony Nigro, Bijoy Panicker, Arno G. Steinig, Qingua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun
  • 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
    Patent number: 8101613
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: January 24, 2012
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Lee D. Arnold, Cara Cesario, Heather Coate, Andrew Philip Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark J. Mulvihill, Anthony I. Nigro, Bijoy Panicker, Amo G. Steinig, Yingchuan Sun, Qinghua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang
  • KINASE INHIBITORS AND METHOD OF TREATING CANCER
    Publication number: 20110263598
    Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
    Type: Application
    Filed: April 6, 2011
    Publication date: October 27, 2011
    Applicant: UNIVERSITY HEALTH NETWORKS
    Inventors: Peter B. Sampson, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Heinz W. Pauls, Louise G. Edwards, Miklos Feher, Narendra Kumar B. Patel, Radoslaw Laufer, Guohua Pan
  • INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER
    Publication number: 20110065702
    Abstract: The present invention is directed to a compound is represented by Structural Formula (A):or a pharmaceutically acceptable salt therof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 19, 2008
    Publication date: March 17, 2011
    Inventors: Heinz W. Pauls, Bryan T. Forrest, Radoslaw Laufer, Miklos Feher, Peter Brent Sampson, Guohua Pan, Sze-Wan Li, Yong Liu
  • CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER
    Publication number: 20110015174
    Abstract: A CPT1 inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 1, 2008
    Publication date: January 20, 2011
    Applicant: University Health Network
    Inventors: Heinz W. Pauls, Bryan T. Forrest, Peter Brent Sampson, Yong Liu, Radoslaw Laufer, Yunhui Lang, Miklos Feher, Yi Yao, Guohua Pan
  • 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
    Patent number: 7820662
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: October 26, 2010
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Lee D. Arnold, Cara Cesario, Heather Coate, Andrew Philip Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark J. Mulvihill, Anthony I. Nigro, Bijoy Panicker, Arno G. Steinig, Yingchuan Sun, Quinghua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang
  • N-substituted imidazopyridine c-Kit inhibitors
    Patent number: 7767673
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-Oxide thereof, are useful in the treatment of cancer.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: August 3, 2010
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Arlindo L. Castelhano, Andrew P. Crew, Han-Qing Dong, Radoslaw Laufer, An-Hu Li, Li Qiu, Colin Peter Sambrook Smith, Tao Zhang
  • INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER
    Publication number: 20100105900
    Abstract: A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 9, 2008
    Publication date: April 29, 2010
    Inventors: Heinz W. Pauls, Peter Brent Sampson, Bryan T. Forrest, Radoslaw Laufer, Yong Liu, Miklos Feher, Yi Yao, Guohua Pan
  • Bicyclic protein kinase inhibitors
    Patent number: 7648987
    Abstract: Compounds of the Formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit protein kinase enzymes and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: January 19, 2010
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Andrew Philip Crew, Han-Qing Dong, Mark Joseph Mulvihill, Douglas S. Werner, Mridula Kadalbajoo, Radoslaw Laufer
  • 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors
    Publication number: 20090325928
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Application
    Filed: August 12, 2009
    Publication date: December 31, 2009
    Inventors: Lee D. Arnold, Heather Coate, Andrew Philip Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark Joseph Mulvihill, Anthony Nigro, Bijoy Panicker, Arno G. Steinig, Qingua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun
  • 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors
    Publication number: 20090118499
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Application
    Filed: October 3, 2008
    Publication date: May 7, 2009
    Inventors: Lee D. Arnold, Heather Coate, Andrew Philip Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark Joseph Mulvihill, Anthony Nigro, Bijoy Panicker, Arno G. Steinig, Quinghua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun
  • N-substituted benzimidazolyl c-Kit inhibitors
    Patent number: 7521448
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.
    Type: Grant
    Filed: August 16, 2004
    Date of Patent: April 21, 2009
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Joshua Bolger, Arlindo L. Castelhano, Andrew Phillip Crew, Han-Qing Dong, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Mulvihill, Li Qiu, Colin Peter Sambrook Smith, Yingchaun Sun, Graham Michael Wynne, Tao Zhang
  • N-Substituted Imidazopyridine c-Kit Inhibitors
    Publication number: 20090062275
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.
    Type: Application
    Filed: September 12, 2008
    Publication date: March 5, 2009
    Inventors: Arlindo L. Castelhano, Andrew Phillip Crew, Han-Qing Dong, Radoslaw Laufer, An-Hu Li, Li Qiu, Colin Peter Sambrook Smith, Tao Zhang
  • N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors
    Patent number: 7485658
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.
    Type: Grant
    Filed: August 16, 2004
    Date of Patent: February 3, 2009
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Joshua Bolger, Arlindo L. Castelhano, Andrew Phillip Crew, Radoslaw Laufer, An-Hu Li, Colin Peter Sambrook Smith, Yingchuan Sun
  • N3-substituted imidazopyridine c-Kit inhibitors
    Patent number: 7442709
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.
    Type: Grant
    Filed: August 16, 2004
    Date of Patent: October 28, 2008
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Arlindo L. Castelhano, Andrew Phillip Crew, Han-Qing Dong, Radoslaw Laufer, An-Hu Li, Li Qiu, Colin Peter Sambrook Smith, Tao Zhang
  • N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors
    Publication number: 20080221187
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.
    Type: Application
    Filed: August 16, 2004
    Publication date: September 11, 2008
    Inventors: Joshua Bolger, Arlindo Castelhano, Andrew Crew, Radoslaw Laufer, An-Hu Li, Colin Sambrook Smith, Yingchuan Sun